Company
Headquarters: Westport, CT, United States
Employees: 49
CEO: Mr. Kenneth L. Londoner M.B.A., MBA
$109.7 Million
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Abbott | $216.15 B |
| Boston Scientific Corporation | $140.40 B |
| Stryker | $133.15 B |
| Medtronic | $123.20 B |
| Edwards Lifesciences Corporation | $50.10 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation and ventricular tachycardia. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | $13,000 |
| EBITDA | $-26,845,000 |
| Gross Profit TTM | $13,000 |
| Profit Margin | 0.00% |
| Operating Margin | -211407.70% |
| Quarterly Revenue Growth | % |
BioSig Technologies, Inc. has the following listings and related stock indices.
Stock: NASDAQ: BSGM wb_incandescent